Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure

Experimental Physiology

Volumn 93, Issue 3, 2008, Pages 434-442

  Ray, L ^a   Mathieu, M ^a   Jespers, P ^a   Hadad, I ^a   Mahmoudabady, M ^a   Pensis, A ^a   Motte, S ^a   Peters, I R ^b   Naeije, R ^a   McEntee, K ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; BONE MORPHOGENETIC PROTEIN 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; PROCOLLAGEN C PROTEINASE; SEROTONIN 2B RECEPTOR; SEROTONIN TRANSPORTER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOG; GENE EXPRESSION; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; MALE; MAMMARY ARTERY; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION;

EID: 39149105241     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2007.040469     Document Type: Article

References (45)

1. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC & Morrell NW (2002). Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672 1678.
2. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H & Schäfers HJ (2002). Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105, 1034 1036.
3. Ben Driss A, Devaux C, Henrion D, Duriez M, Thuillez C, Levy BI & Michel JB (2000). Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure. Circulation 101, 2764 2770.
4. Black SM, Fineman JR, Steinhorn RH, Bristow J & Soifer RJ (1998). Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Heart Circ Physiol 275, H1643 H1651.
5. Black SM, Mata-Greenwood E, Dettman RW, Ovadia B, Fitzgerald RK, Reinhartz O, Thelitz S, Steinhorn RH, Gerrets R, Hendricks-Munoz K, Ross GA, Bekker JM, Johengen MJ & Fineman JR (2003). Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation 108, 1646 1654.
6. Carpenter TC, Schomberg S & Stenmark KR (2005). Endothelin-mediated increases in lung VEGF content promote vascular leak in young rats exposed to viral infection and hypoxia. Am J Physiol Lung Cell Mol Physiol 289, L1075 L1082.
7. Christou H, Yoshida A, Arthur V, Morita T & Kouroumbanas S (1998). Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 18, 768 776.
8. Chu D, Sullivan CC, Du L, Cho AJ, Kido M, Wolf PL, Weitzman MD, Jamieson SW & Thistlethwaite PA (2004). A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin-1. Ann Thorac Surg 77, 449 456.
9. Cody RJ, Haas GJ, Binkley PF, Capers Q & Kelley R (1992). Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85, 504 509.
10. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE & Knowles JA (2000). Familial primary pulmonary hypertension gene PPH1 is caused by mutations in bone morphogenetic protein receptor-II gene. Am J Hum Genet 67, 737 744.
11. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deu R, Jamieson SW & Thistlethwaite PA (2003). Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348, 500 509.
12. Everett AD, Le Cras TD, Xue C & Johns RA (1998). eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol Lung Cell Mol Physiol 274, L1058 L1065.
13. Fang ZY & Marwick TH (2002). Vascular dysfunction and heart failure: epiphenomenon or etiologic agent? Am Heart J 143, 383 390.
14. Farber HW & Loscalzo J (2004). Pulmonary arterial hypertension. N Engl J Med 351, 1655 1665.
15. Forster C & Armstrong PW (1990). Pacing-induced heart failure in the dog: evaluation of peripheral vascular α-adrenoceptor subtypes. Cardiovasc Pharmacol 16, 708 718.
16. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP & Stewart DJ (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328, 1732 1739.
17. Girard C, Lehot JJ, Pannetier SC, Filley S, Ffrench P & Estanove S (1992). Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension. Anesthesiology 77, 880 883.
18. Grover TR, Parker TA, Markham NE & Abman SH (2005). rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. Am J Physiol Lung Cell Mol Physiol 289, L315 L321.
19. Kelland NF & Webb DJ (2006). Minireview. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med 231, 696 699.
20. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, Nichols WC & Trembath RC (2000). Heterozygous germline mutations in a TGF-β receptor, BMPR2, are the cause of familial primary pulmonary hypertension. Nat Genet 26, 81 84.
21. Lavallée M, Takamura M, Parent R & Thorin E (2001). Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Failure Rev 6, 265 276.
22. Li H, Elton TS, Chen YF & Oparil S (1994). Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol Lung Cell Mol Physiol 266, L553 L560.
23. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC & Morrell NW (2006). Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98, 818 827.
24. Luchner A, Jougasaki M, Friedrich E, Friedrich E, Borgeson DD, Stevens TL, Redfield MM, Riegger GA & Burnett JC Jr. (2000). Activation of cardiorenal and pulmonary tissue endothelin-1 in experimental heart failure. Am J Physiol Regul Integr Comp Physiol 279, R974 R979.
25. MacLean MR, Hervé P, Eddahibi S & Adnot S (2000). 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131, 161 168.
26. Mata-Greenwood E, Meyrick B, Soifer SJ, Fineman JR & Black SM (2003). Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285, L222 L231.
27. Moraes DL, Colucci WS & Givertz MM (2000). Secondary pulmonary hypertension in chronic heart failure: the role of endothelium in pathophysiology and management. Circulation 102, 1718 1723.
28. Motte S, Naeije R & McEntee K (2006). Endothelin receptor antagonists. Pulm Pharmacol 110, 386 414.
29. Motte S, van Beneden R, Mottet J, Rondelet B, Mathieu M, Havaux X, Lause P, Clercx C, Ketelslegers JM, Naeije R & McEntee K (2003). Early activation of cardiac and renal endothelin systems in experimental heart failure. Am J Physiol Heart Circ Physiol 285, H2482 H2491.
30. Naeije R, Lipski A, Abramowicz M, Lejeune P, Mélot C, Antoine M, De Smet JM, Leclerc JL & Primo G (1994). Nature of pulmonary hypertension in congestive heart failure. Effects of cardiac transplantation. Am J Respir Crit Care Med 149, 881 887.
31. Ontkean M, Ray R & Greenberg B (1991). Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69, 1088 1096.
32. Ooi H, Colucci WS & Givertz MM (2002). Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation 106, 1618 1621.
33. Partovian C, Adnot S, Raffestin B, Louzier V, Levame M, Mavier IM, Lemarchand P & Eddahibi S (2000). Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 23, 762 771.
34. Pereira RB, Sartorio CL, Vassallo DV & Stefanon I (2005). Differences in tail vascular bed reactivity in rats with and without heart failure following myocardial infarction. J Pharmacol Exp Ther 312, 1321 1325.
35. Rondelet B, Kerbaul F, Motte S, Van Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon I, Ketelslegers JM & Naeije R (2003). Bosentan for the prevention of overcirculation-induced experimental pulmonary hypertension. Circulation 107, 1329 1335.
36. Rondelet B, Kerbaul F, Van Beneden R, Motte S, Fesler P, Hubloue I, Remmelink M, Brimioulle S, Salmon I, Ketelslegers JM & Naeije R (2004). Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 110, 2220 2225.
37. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K & Sugishita Y (1996). Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol 28, 1580 1588.
38. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S & Fishman A (2004). Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43, 5S 12S.
39. Sullivan CC, Du L, Chu D, Cho AJ, Kido M, Wolf PL, Jamieson SW & Thistlethwaite PA (2003). Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway. Proc Natl Acad Sci U S A 100, 12331 12336.
40. Townsley MI, Pitts VH, Ardell JL, Zhao Z & Johnson WH Jr. (1994). Altered pulmonary microvascular reactivity to norepinephrine in canine pacing-induced heart failure. Circ Res 75, 347 356.
41. Townsley MI, Snell KS, Ivey CL, Culberson DE, Liu DC, Reed RK & Mathieu-Costello O (1999). Remodeling of lung interstitium but not resistance vessels in canine pacing-induced heart failure. J Appl Physiol 87, 1823 1830.
42. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM & Voelkel NF (2001). Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195, 367 374.
43. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM & Gail DB (2006a). Right ventricular function and failure. Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Circulation 114, 1883 1891.
44. Voelkel NF, Vandivier RW & Tuder RM (2006b). Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 290, L209 L221.
45. Winer J, Jung CK, Shackel I & Williams PL (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270, 41 49.